Huakang Biomedical Holdings Company Limited provided earnings guidance for the six months ended June 30, 2019. For the six months, the company expects to record a decrease in revenue for the six months ended 30 June 2019 (the "2019 Interim Revenue") by approximately 12.9% as compared with that of the corresponding period of 2018. The Group is also expected to record a decrease in profit before listing expenses for the six months ended 30 June 2019 (the "2019 Interim Profit") by approximately 88.8% as compared with that of the corresponding period of 2018.